Management of acute rejection in paediatric liver transplantation

Pediatric Drugs

Volumn 15, Issue 6, 2013, Pages 459-471

  Thangarajah, D ^a   O'Meara, M ^a   Dhawan, A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AZATHIOPRINE; B7 ANTIGEN; BASILIXIMAB; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; DNA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; JANUS KINASE 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; BILE DUCT DISEASE; BILE DUCT INFECTION; CD4+ T LYMPHOCYTE; CELL DEATH; CELL DIVISION; CYTOKINE RELEASE; CYTOLYSIS; DNA SYNTHESIS; DRUG MEGADOSE; EARLY DIAGNOSIS; ENZYME ACTIVATION; FEVER; G1 PHASE CELL CYCLE CHECKPOINT; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS; HEPATOMEGALY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; KIDNEY DISEASE; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MAINTENANCE THERAPY; MALAISE; NONHUMAN; PEDIATRIC SURGERY; PORTAL INFLAMMATION; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; REVIEW; SURVIVAL RATE; SYMPTOM ASSESSMENT; T LYMPHOCYTE ACTIVATION; VASCULITIS; VENOUS INFLAMMATION;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CHEMORADIOTHERAPY, ADJUVANT; CHILD; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MAINTENANCE CHEMOTHERAPY;

EID: 84890545702     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0034-4     Document Type: Review

References (51)

1. Hatch D. Mechanisms of acute rejection in the renal allograft. 2001.
2. Muiesan P, Vergani D, Mieli-Vergani G. Liver transplantation in children. J Hepatol. 2007;46(2):340-8 (Epub 2006/12/13).
3. Ng VL, Fecteau A, Shepherd R, Magee J, Bucuvalas J, Alonso E, et al. Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a north american multicenter registry. Pediatrics. 2008;122(6):e1128-35 (Epub 2008/12/03).
4. Ng VL, Alonso EM, Bucuvalas JC, Cohen G, Limbers CA, Varni JW, et al. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: report of the studies of pediatric liver transplantation experience. J Pediatrics. 2012;160(5):820-6 e3 (Epub 2011/12/24).
5. Calne R. WOFIE hypothesis: some thoughts on an approach toward allograft tolerance. Transplantat Proc. 1996;28(3):1152 (Epub 1996/06/01).
6. Encke J, Uhl W, Stremmel W, Sauer P. Immunosuppression and modulation in liver transplantation. Nephrol Dial Transplant. 2004;19 Suppl 4:iv22-5 (Epub 2004/07/09).
7. Terminology for hepatic allograft rejection. International Working Party. Hepatology. 1995;22(2):648-54 (Epub 1995/08/01).
8. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25(3):658-63 (Epub 1997/03/01).
9. Peakman M, Vergani D. In: Horne T, editor. Basic and clinical immunology. 2nd ed. London: Churchill Livingstone Elsevier; 2009.
10. Mazariegos GV, Machaidze Z. Pediatric liver transplantation: review of literature 2005-2006. Pediatr Transplant. 2007;11:835-43.
11. Liver immunology JN. Principles and practice. Totowa, New Jersey: Humana Press; 2007.
12. Neil DA, Hubscher SG. Current views on rejection pathology in liver transplantation. Transplant Int. 2010;23(10):971-83 (Epub 2010/08/21).
13. Coelho T, Tredger M, Dhawan A. Current status of immunosuppressive agents for solid organ transplantation in children. Pediatr Transplant. 2012;16(2):106-22 (Epub 2012/03/01).
14. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-67 (Epub 2003/09/19).
15. Spada M, Petz W, Bertani A, Riva S, Sonzogni A, Giovannelli M, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant. 2006;6(8):1913-21 (Epub 2006/06/15).
16. del Mar Fernandez De Gatta M, Santos-Buelga D, Dominguez-Gil A, Garcia MJ. Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2002;41(2):115-35 (Epub 2002/03/13).
17. Zhao W, Fakhoury M, Jacqz-Aigrain E. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation. Ther Drug Monit. 2010;32(6):688-99 (Epub 2010/11/12).
18. Ganschow R, Grabhorn E, Schulz A, Von Hugo A, Rogiers X, Burdelski M. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients. Pediatr Transplant. 2005;9(6):741-5 (Epub 2005/11/05).
19. Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. Transplantation. 2003;75(6):796-9 (Epub 2003/03/28).
20. Gibelli NE, Pinho-Apezzato ML, Miyatani HT, Maksoud-Filho JG, Silva MM, Ayoub AA, et al. Basiliximab-chimeric anti-IL2-R monoclonal antibody in pediatric liver transplantation: comparative study. Transplant Proc. 2004;36(4):956-7 (Epub 2004/06/15).
21. Ramirez Cabrera M. Optimizing use of basiliximab in liver transplantation. Transplant Res Risk Manage. 2010;2:1-10.
22. Reding R, Gras J, Sokal E, Otte JB, Davies HF. Steroid-free liver transplantation in children. Lancet. 2003;362(9401):2068-70 (Epub 2003/12/31).
23. Gras JM, Gerkens S, Beguin C, Janssen M, Smets F, Otte JB, et al. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transplant. 2008;14(4):469-77 (Epub 2008/04/03).
24. Strassburg A, Pfister ED, Arning A, Nashan B, Ehrich JH, Melter M. Basiliximab reduces acute liver allograft rejection in pediatric patients. Transplant Proc. 2002;34(6):2374-5 (Epub 2002/09/25).
25. Asensio M, Margarit C, Chavez R, Ortega J, Charco R, Iglesias J. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids. Transplant Proc. 2002;34(5):1970-1 (Epub 2002/08/15).
26. Kovarik JM, Gridelli BG, Martin S, Rodeck B, Melter M, Dunn SP, et al. Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm. Pediatr Transplant. 2002;6(3):224-30 (Epub 2002/07/09).
27. Unit KsCPL. Paediatric liver transplantation guidelines. Use of alemtuzumab (MacCampath) in paediatric liver transplant patients. London: King's College Hospital; 2009.
28. Kato T, Selvaggi G, Panagiotis T, Hernandez E, McLaughlin G, Moon J, et al. Pediatric liver transplant with Campath 1H induction - preliminary report. Transplant Proc. 2006;38(10):3609-11 (Epub 2006/12/19).
29. Jain A, Mazariegos G, Kashyap R, Green M, Gronsky C, Starzl TE, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation. 2000;70(4):617-25 (Epub 2000/09/06).
30. Jain A, Singhal A, Fontes P, Mazariegos G, DeVera ME, Cacciarelli T, et al. One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. Transplantation. 2011;91(9):1025-30 (Epub 2011/03/08).
31. Reyes J, Jain A, Mazariegos G, Kashyap R, Green M, Iurlano K, et al. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation. 2000;69(12):2573-80 (Epub 2000/07/26).
32. Unit KsCPL. Paediatric transplantation guidelines. Tacrolimus immunosuppression protocol for paediatric transplantation. London: King's College; 2010.
33. Evans HM, McKiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation. 2005;79(11):1575-80 (Epub 2005/06/09).
34. Chardot C, Nicoluzzi JE, Janssen M, Sokal E, Lerut J, Otte JB, et al. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation. 2001;71(2):224-9 (Epub 2001/02/24).
35. Aw MM, Verma A, Rela M, Heaton N, Mieli-Vergani G, Dhawan A. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients. Liver Transplant. 2008;14(9):1303-8 (Epub 2008/08/30).
36. Germani G, Pleguezuelo M, Villamil F, Vaghjiani S, Tsochatzis E, Andreana L, et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant. 2009;9(8):1725-31 (Epub 2009/06/23).
37. Marin Gomez LM, Loinaz Segurota C, Moreno Gonzalez E, Moreno Elola-Olaso A, Gonzalez-Pinto Arrillaga I, Meneu Diaz JC, et al. The influence of immunosuppression switching in liver function in adult hepatic transplantation. Hepatogastroenterology. 2011;58(106):532-5 (Epub 2011/06/15).
38. Unit KsCPl. Paediatric liver transplantation guidelines. Azathioprine use in paediatric liver transplantation. London: King's College; 2010.
39. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999;67(7):1036-42 (Epub 1999/04/30).
40. Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75(10):1710-7 (Epub 2003/06/05).
41. Zaghla H, Selby RR, Chan LS, Kahn JA, Donovan JA, Jabbour N, et al. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther. 2006;23(4):513-20 (Epub 2006/01/31).
42. Sindhi R, Ganjoo J, McGhee W, Mazariegos G, Reyes J. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants. Transplant Proc. 2002;34(5):1972-3 (Epub 2002/08/15).
43. Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. Pediatr Transplant. 2005;9(3):269-76 (Epub 2005/05/25).
44. Basso MS, Subramaniam P, Tredger M, Verma A, Heaton N, Rela M, et al. Sirolimus as renal and immunological rescue agent in pediatric liver transplant recipients. Pediatr Transplant. 2011;15(7):722-7 (Epub 2011/10/19).
45. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant. 2006;6(7):1578-85 (Epub 2006/07/11).
46. Martin SR, Atkison P, Anand R, Lindblad AS. Studies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr Transplant. 2004;8(3):273-83 (Epub 2004/06/05).
47. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis. 2009;29(1):91-101 (Epub 2009/02/25).
48. Brayman K. New insights into the mechanisms of action of thymoglobulin. Transplantation. 2007;84(11S).
49. Kerkar N, Morotti RA, Iyer K, Arnon R, Miloh T, Sturdevant M, et al. Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients. Clin Transplant. 2011;25(6):E584-91 (Epub 2011/09/17).
50. D'Antiga L, Dhawan A, Portmann B, Francavilla R, Rela M, Heaton N, et al. Late cellular rejection in paediatric liver transplantation: aetiology and outcome. Transplantation. 2002;73(1):80-4 (Epub 2002/01/17).
51. Soltys KA, Mazariegos GV, Squires RH, Sindhi RK, Anand R. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant. 2007;7(9):2165-71 (Epub 2007/07/05).